...
首页> 外文期刊>Journal of biopharmaceutical statistics >Median-based incremental cost-effectiveness ratios with censored data
【24h】

Median-based incremental cost-effectiveness ratios with censored data

机译:带有审查数据的基于中位数的增量成本效益比

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.
机译:除有效性外,成本效益是治疗评估的重要组成部分。在成本效益分析中,一种被称为增量成本效益比(ICER)的度量得到了广泛使用,并且平均成本和平均(质量调整后的)寿命年已成为总结研究人群成本和有效性的标准。 。最近,基于中值的ICER被提出用于互补或敏感性分析。在本文中,我们将在检查某些数据时扩展此方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号